The biotech will add a pivotal Phase III cohort to its ongoing Phase I/II trial evaluating ATSN-201 in X-linked retinoschisis ...

Bioluminescent imaging is helping researchers better understand the effectiveness of tissue regeneration enhancers delivered to injured heart tissue by different adeno-associated virus vectors.

Beacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova.

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

In the July 2 release, 4DMT explained that the 25% layoffs are part of a move to “streamline operations to offset additional ...

The Hopewell site is equipped to support clinical-stage development, process-development, and scaleup for cell and gene therapy programs.

Researchers tested a gene therapy that restored partial hearing in patients with OTOF gene mutations causing congenital ...

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...

ProBio has opened its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell ...

ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today ...